TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Bioxyne Limited ( (AU:BXN) ) just unveiled an announcement.
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has announced the release of GMP manufactured MDMA capsules for clinical trials in Victoria and authorized prescriber dispensing in Queensland. This strategic move positions Bioxyne at the forefront of innovative mental health treatments in Australia, addressing the significant need for effective PTSD therapies and leveraging the growing global psychedelic drugs market.
More about Bioxyne Limited
Bioxyne Limited is an Australian pharmaceutical company focused on developing and commercializing innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, the company is expanding into the production of psychedelic compounds for therapeutic use.
Average Trading Volume: 4,180,386
Technical Sentiment Signal: Buy
Current Market Cap: A$85.4M
See more insights into BXN stock on TipRanks’ Stock Analysis page.